ReviewClinical and vaccine immunology : CVI2017
Update on Chlamydia trachomatis Vaccinology.
Review in Clinical and vaccine immunology : CVI, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 79 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
79 citing papers in PubMed, 1 synthesis or guideline pooled it, 117 citations in OpenAlex.
- Effect of Chlamydia trachomatis on adverse pregnancy outcomes: a meta-analysis.Archives of gynecology and obstetrics · 2020Pooled it
- Immunization with a multisubunit vaccine induces immunological memory and cross-protective immunity against heterologousFrontiers in cellular and infection microbiology · 2026Article
- Impact of oralmSystems · 2025Article
- Profile ofHuman vaccines & immunotherapeutics · 2025Article
- Design of a Multi-Epitope Vaccine using β-barrel Outer Membrane Proteins Identified in Chlamydia trachomatis.The Journal of membrane biology · 2025Article
- Study Models forMicroorganisms · 2025Review
- A VCG-Based MultiepitopeBiomedicines · 2025Article
- Antibacterial effects of coniferyl alcohol-derived dehydrogenation polymer on chlamydial infectionFrontiers in chemistry · 2025Article
- Interferon-γ Responses to Chlamydia trachomatis Vaccine Candidate Proteins in Women With Different Chlamydia Outcomes.The Journal of infectious diseases · 2024Article
- Chlamydia trachomatis Seroassays Used in Epidemiologic Research: A Narrative Review and Practical Considerations.The Journal of infectious diseases · 2024Review
- Combination of compound screening with an animal model identifies pentamidine to prevent Chlamydia trachomatis infection.Cell reports. Medicine · 2024Article
- TheMicrobiology spectrum · 2024Article
- Insights into Chlamydia Development and Host Cells Response.Microorganisms · 2024Review
- Safety and efficacy of C. muridarum vaccines adjuvanted with CpG-1826 and four concentrations of Montanide-ISA-720-VG.NPJ vaccines · 2024Article
- Effects of prime-boost strategies on the protective efficacy and immunogenicity of a PLGA (85:15)-encapsulated Chlamydia recombinant MOMP nanovaccine.Pathogens and disease · 2024Article
- Diverse animal models forFrontiers in microbiology · 2024Review
- Review
- Elimination of Chlamydia muridarum from the female reproductive tract is IL-12p40 dependent, but independent of Th1 and Th2 cells.PLoS pathogens · 2024Article
- Article
- Ensuring equity with pre-clinical planning for chlamydia vaccines.NPJ vaccines · 2023Review
19 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 3 institutions in 2 countries.
Funding
Abstract
Attempts to produce a vaccine to protect against
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.